Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC as maintenance therapy in ulcerative colitis (Japan)
jRCT2031250197Phase 3Active, not recruiting
- Sponsor
- Celltrion Healthcare
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab-dyyb in autoimmune colitis, sponsored by Celltrion Healthcare. Primary endpoint: Clinical remission at Week 44. Started Aug 2025; status: active, not recruiting.
02
Drugs
infliximab-dyyb
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031250197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250197.